103 related articles for article (PubMed ID: 10680591)
1. Anti-malignin antibody in serum and other tumor marker determinations in breast cancer.
Thornthwaite JT
Cancer Lett; 2000 Jan; 148(1):39-48. PubMed ID: 10680591
[TBL] [Abstract][Full Text] [Related]
2. Discrimination of breast cancer by anti-malignin antibody serum test in women undergoing biopsy.
Harman SM; Gucciardo F; Heward CB; Granstrom P; Barclay-White B; Rogers LW; Ibarra JA
Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2310-5. PubMed ID: 16214910
[TBL] [Abstract][Full Text] [Related]
3. Anti-malignin antibody evaluation: a possible challenge for cancer management.
Botti C; Martinetti A; Nerini-Molteni S; Ferrari L
Int J Biol Markers; 1997; 12(4):141-7. PubMed ID: 9582602
[TBL] [Abstract][Full Text] [Related]
4. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
5. Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma.
Goldenberg DM; Abdel-Nabi H; Sullivan CL; Serafini A; Seldin D; Barron B; Lamki L; Line B; Wegener WA
Cancer; 2000 Jul; 89(1):104-15. PubMed ID: 10897007
[TBL] [Abstract][Full Text] [Related]
6. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
7. Malignin antibody and early malignancy.
Bogoch S; Bogoch ES
Lancet; 1991 Apr; 337(8747):977. PubMed ID: 1678055
[No Abstract] [Full Text] [Related]
8. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
9. Anti-thyroid peroxidase antibodies are associated with the absence of distant metastases in patients with newly diagnosed breast cancer.
Farahati J; Roggenbuck D; Gilman E; Schütte M; Jagminaite E; Seyed Zakavi R; Löning T; Heissen E
Clin Chem Lab Med; 2012 Apr; 50(4):709-14. PubMed ID: 22149743
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.
Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC
Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911
[TBL] [Abstract][Full Text] [Related]
13. The immunoscintigraphic use of Tc-99m-labelled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer.
Lind P; Smola MG; Lechner P; Ratschek M; Klima G; Költringer P; Steindorfer P; Eber O
Int J Cancer; 1991 Apr; 47(6):865-9. PubMed ID: 2010229
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.
Berg WA; Gutierrez L; NessAiver MS; Carter WB; Bhargavan M; Lewis RS; Ioffe OB
Radiology; 2004 Dec; 233(3):830-49. PubMed ID: 15486214
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
Maccio G; Goussot V; Berriolo-Riedinger A; Riedinger JM
Ann Biol Clin (Paris); 2017 Aug; 75(4):431-441. PubMed ID: 28751288
[TBL] [Abstract][Full Text] [Related]
16. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
18. Studies of breast cancer imaging with radiolabeled antibodies to carcinoembryonic antigen. Immunomedics Breast Cancer Study Group.
Goldenberg DM; Wegener W
Acta Med Austriaca; 1997; 24(2):55-9. PubMed ID: 9227788
[TBL] [Abstract][Full Text] [Related]
19. Is parathyroid hormone-related protein a sensitive serum marker in advanced breast cancer?
Pyke CM; Menezes G; Purdie DM; Johnson S; Cowley D
Aust N Z J Surg; 1997 May; 67(5):256-9. PubMed ID: 9152154
[TBL] [Abstract][Full Text] [Related]
20. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
